106 related articles for article (PubMed ID: 19943198)
1. Kinase inhibitor selectivity.
Bhagwat SS
Curr Opin Investig Drugs; 2009 Dec; 10(12):1266-8. PubMed ID: 19943198
[No Abstract] [Full Text] [Related]
2. Challenges in design of biochemical assays for the identification of small molecules to target multiple conformations of protein kinases.
Chène P
Drug Discov Today; 2008 Jun; 13(11-12):522-9. PubMed ID: 18549979
[TBL] [Abstract][Full Text] [Related]
3. CHI's Fourth Annual Drug Discovery Chemistry Conference. Kinase inhibitor chemistry: charting the chemical space. 7-8 April 2009, San Diego, CA, USA.
Seneci P
IDrugs; 2009 Jun; 12(6):358-62. PubMed ID: 19517315
[No Abstract] [Full Text] [Related]
4. A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding.
Bogoyevitch MA; Fairlie DP
Drug Discov Today; 2007 Aug; 12(15-16):622-33. PubMed ID: 17706543
[TBL] [Abstract][Full Text] [Related]
5. Kinase-targeted libraries: the design and synthesis of novel, potent, and selective kinase inhibitors.
Akritopoulou-Zanze I; Hajduk PJ
Drug Discov Today; 2009 Mar; 14(5-6):291-7. PubMed ID: 19121409
[TBL] [Abstract][Full Text] [Related]
6. Identification of polyoxometalates as nanomolar noncompetitive inhibitors of protein kinase CK2.
Prudent R; Moucadel V; Laudet B; Barette C; Lafanechère L; Hasenknopf B; Li J; Bareyt S; Lacôte E; Thorimbert S; Malacria M; Gouzerh P; Cochet C
Chem Biol; 2008 Jul; 15(7):683-92. PubMed ID: 18635005
[TBL] [Abstract][Full Text] [Related]
7. [Progress in the design of selective ATP-competitive kinase inhibitors].
Deng XQ; Xiang ML; Jia R; Yang SY
Yao Xue Xue Bao; 2007 Dec; 42(12):1232-6. PubMed ID: 18338633
[TBL] [Abstract][Full Text] [Related]
8. [Kinase inhibitors].
Hagiwara M; Usuki H
Tanpakushitsu Kakusan Koso; 2007 Oct; 52(13 Suppl):1708-12. PubMed ID: 18051404
[No Abstract] [Full Text] [Related]
9. The design and synthesis of novel alpha-ketoamide-based p38 MAP kinase inhibitors.
Montalban AG; Boman E; Chang CD; Ceide SC; Dahl R; Dalesandro D; Delaet NG; Erb E; Ernst JT; Gibbs A; Kahl J; Kessler L; Lundström J; Miller S; Nakanishi H; Roberts E; Saiah E; Sullivan R; Wang Z; Larson CJ
Bioorg Med Chem Lett; 2008 Mar; 18(6):1772-7. PubMed ID: 18325768
[TBL] [Abstract][Full Text] [Related]
10. High-throughput kinase profiling as a platform for drug discovery.
Goldstein DM; Gray NS; Zarrinkar PP
Nat Rev Drug Discov; 2008 May; 7(5):391-7. PubMed ID: 18404149
[TBL] [Abstract][Full Text] [Related]
11. Benzothiophene inhibitors of MK2. Part 2: improvements in kinase selectivity and cell potency.
Anderson DR; Meyers MJ; Kurumbail RG; Caspers N; Poda GI; Long SA; Pierce BS; Mahoney MW; Mourey RJ; Parikh MD
Bioorg Med Chem Lett; 2009 Aug; 19(16):4882-4. PubMed ID: 19616942
[TBL] [Abstract][Full Text] [Related]
12. Tricyclic azepine derivatives: pyrimido[4,5-b]-1,4-benzoxazepines as a novel class of epidermal growth factor receptor kinase inhibitors.
Smith L; Piatnitski EL; Kiselyov AS; Ouyang X; Chen X; Burdzovic-Wizemann S; Xu Y; Pan W; Chen X; Wang Y; Rosler RL; Patel SN; Chiang HH; Milligan DL; Columbus J; Wong WC; Doody JF; Hadari YR
Bioorg Med Chem Lett; 2006 Mar; 16(6):1643-6. PubMed ID: 16412636
[TBL] [Abstract][Full Text] [Related]
13. The ATP site of protein kinases as target for drug development: from natural compounds to gleevec.
Granot Y
Isr Med Assoc J; 2002 Aug; 4(8):633-5. PubMed ID: 12183872
[No Abstract] [Full Text] [Related]
14. Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitors.
Dwyer MP; Paruch K; Alvarez C; Doll RJ; Keertikar K; Duca J; Fischmann TO; Hruza A; Madison V; Lees E; Parry D; Seghezzi W; Sgambellone N; Shanahan F; Wiswell D; Guzi TJ
Bioorg Med Chem Lett; 2007 Nov; 17(22):6216-9. PubMed ID: 17904366
[TBL] [Abstract][Full Text] [Related]
15. Structural biology contributions to tyrosine kinase drug discovery.
Cowan-Jacob SW; Möbitz H; Fabbro D
Curr Opin Cell Biol; 2009 Apr; 21(2):280-7. PubMed ID: 19208462
[TBL] [Abstract][Full Text] [Related]
16. Selectivity assessment of kinase inhibitors: strategies and challenges.
Luo Y
Curr Opin Mol Ther; 2005 Jun; 7(3):251-5. PubMed ID: 15977423
[TBL] [Abstract][Full Text] [Related]
17. The role of structure in kinase-targeted inhibitor design.
Pratt DJ; Endicott JA; Noble ME
Curr Opin Drug Discov Devel; 2004 Jul; 7(4):428-36. PubMed ID: 15338952
[TBL] [Abstract][Full Text] [Related]
18. Identification and SAR of squarate inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2).
Lovering F; Kirincich S; Wang W; Combs K; Resnick L; Sabalski JE; Butera J; Liu J; Parris K; Telliez JB
Bioorg Med Chem; 2009 May; 17(9):3342-51. PubMed ID: 19364658
[TBL] [Abstract][Full Text] [Related]
19. Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors.
Simard JR; Getlik M; Grütter C; Pawar V; Wulfert S; Rabiller M; Rauh D
J Am Chem Soc; 2009 Sep; 131(37):13286-96. PubMed ID: 19572644
[TBL] [Abstract][Full Text] [Related]
20. Non-ATP competitive protein kinase inhibitors as anti-tumor therapeutics.
Kirkland LO; McInnes C
Biochem Pharmacol; 2009 May; 77(10):1561-71. PubMed ID: 19167366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
